Successful treatment of atopic dermatitis with house dust mite sublingual immunotherapy tablets.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-09-01 DOI:10.12932/AP-231120-1004

Ploykarn Kiatiwat, Wat Mitthamsiri, Tadech Boonpiyathad, Panitan Pradubpongsa, Atik Sangasapaviliya

{"title":"Successful treatment of atopic dermatitis with house dust mite sublingual immunotherapy tablets.","authors":"Ploykarn Kiatiwat, Wat Mitthamsiri, Tadech Boonpiyathad, Panitan Pradubpongsa, Atik Sangasapaviliya","doi":"10.12932/AP-231120-1004","DOIUrl":null,"url":null,"abstract":"Background: Atopic dermatitis (AD) is the most common chronic inflammatory skin disease. Allergen-specific immunotherapy is a treatment option for selected patients with severe AD sensitization to house dust mites (HDM).Objective: To report the first case of successful treatment with HDM sublingual immunotherapy (SLIT) tablets in patients with severe AD.Methods: A Thai male patient with HDM sensitization and severe AD who had not responded to topical corticosteroids and calcineurin inhibitors underwent 1 month of HDM subcutaneous immunotherapy (SCIT), after which his skin symptoms were minimally improved. He lost follow-up SCIT and the symptoms worsened, with large wheal lesions appearing at the SCIT injection site, so we decided to switch from SCIT to HDM SLIT tablets.Results: After the SLIT treatment, the AD and skin lesions improved and the medication could be stopped.Conclusions: HDM SLIT might be an alternative treatment in patients with HDM sensitization and severe AD who are refractory to conventional treatment.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12932/AP-231120-1004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Atopic dermatitis (AD) is the most common chronic inflammatory skin disease. Allergen-specific immunotherapy is a treatment option for selected patients with severe AD sensitization to house dust mites (HDM).

Objective: To report the first case of successful treatment with HDM sublingual immunotherapy (SLIT) tablets in patients with severe AD.

Methods: A Thai male patient with HDM sensitization and severe AD who had not responded to topical corticosteroids and calcineurin inhibitors underwent 1 month of HDM subcutaneous immunotherapy (SCIT), after which his skin symptoms were minimally improved. He lost follow-up SCIT and the symptoms worsened, with large wheal lesions appearing at the SCIT injection site, so we decided to switch from SCIT to HDM SLIT tablets.

Results: After the SLIT treatment, the AD and skin lesions improved and the medication could be stopped.

Conclusions: HDM SLIT might be an alternative treatment in patients with HDM sensitization and severe AD who are refractory to conventional treatment.

查看原文本刊更多论文

使用屋尘螨舌下免疫疗法片剂成功治疗特应性皮炎。

背景：特应性皮炎（AD）是最常见的慢性炎症性皮肤病：特应性皮炎（AD）是最常见的慢性炎症性皮肤病。过敏原特异性免疫疗法是治疗某些对屋尘螨（HDM）过敏的重症特应性皮炎患者的一种选择：报告首例使用 HDM 舌下免疫疗法（SLIT）片剂成功治疗严重 AD 患者的病例：一名泰国男性患者因HDM致敏而患有严重的AD，对外用皮质类固醇激素和钙神经蛋白抑制剂无效，接受了为期1个月的HDM皮下免疫疗法（SCIT），之后他的皮肤症状略有改善。他失去了后续的 SCIT 治疗，而且症状恶化，SCIT 注射部位出现了大面积的荨麻疹皮损，因此我们决定将 SCIT 改为 HDM SLIT 片剂：结果：SLIT 治疗后，AD 和皮损有所改善，可以停药：结论：对于常规治疗无效的 HDM 致敏和严重 AD 患者，HDM SLIT 可能是一种替代治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464